Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeHealthFDA Approves First Pill Containing Human Feces

FDA Approves First Pill Containing Human Feces

Add to Favorite
Added to Favorite
Image by Julien Tromeur from Pixabay

The United States Food and Drug Administration (FDA) has approved the first-ever pill containing human feces for the treatment of recurrent Clostridium difficile (C. difficile) infections. The drug, known as RBX2660, is the first microbiome-based therapy to be approved by the FDA and represents a new frontier in the use of fecal microbiota transplantation (FMT) to treat disease.

  1. difficile infections are a growing problem in healthcare settings, affecting an estimated 500,000 people in the United States each year and causing significant morbidity and mortality. Recurrent infections are particularly difficult to treat, with up to 30% of patients experiencing a second episode within weeks of completing treatment with antibiotics. FMT has emerged as a promising therapy for recurrent C. difficile infections, with a success rate of over 90% in some studies.

RBX2660, developed by Rebiotix, a subsidiary of Ferring Pharmaceuticals, is an oral capsule containing a mix of purified bacteria derived from the feces of healthy donors. The product is designed to restore the balance of gut bacteria in patients with recurrent C. difficile infections, which is thought to be disrupted by repeated antibiotic use.

The approval of RBX2660 by the FDA is based on the results of a phase III clinical trial involving 182 patients with recurrent C. difficile infections. The trial found that RBX2660 was significantly more effective than placebo in preventing recurrent infections, with a success rate of 62.3% compared to 43.7% for placebo.

Organic Greek Vitamin Bottles. Hydrogen Alkaline Generator Water + Filter 4 in 1 Design 500mL (16.9 FL OZ)

The approval of RBX2660 is a significant milestone in the development of microbiome-based therapies and represents a major advance in the use of FMT for the treatment of disease. It is expected to provide a new treatment option for patients with recurrent C. difficile infections who have failed standard antibiotic therapy.

However, the use of FMT and RBX2660 is not without risks. The FDA has issued warnings about the potential transmission of infectious agents, including bacteria, viruses, and parasites, through FMT. Rebiotix has taken steps to mitigate these risks, including screening donors for infectious diseases and using a proprietary purification process to remove potential pathogens from the final product.

In conclusion, the approval of RBX2660 represents an important advance in the use of microbiome-based therapies for the treatment of disease. While there are still risks associated with the use of FMT and RBX2660, these therapies offer a promising new option for patients with recurrent C. difficile infections who have failed standard antibiotic therapy.

References:

  1. Food and Drug Administration. FDA Approves First Microbiome-Based Therapy for Recurrent C. difficile Infection. 2019 May 24. https://www.fda.gov/news-events/press-announcements/fda-approves-first-microbiome-based-therapy-recurrent-c-difficile-infection
  2. Rebiotix. RBX2660. https://www.rebiotix.com/rbx2660/
  3. Kelly CR, et al. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. N Engl J Med. 2016;375:407-416.

Celebrity News Update. Premier Jewelry designer and manufacturer fashion house ParisJewelry.com has started manufacturing a new custom line of celebrity jewelry designs with 30% Off and Free Shipping. Replenish Your Body- Refilter Your Health with OrganicGreek.com Vitamin Bottles, Vitamins and Herbs. Become a WebFans Creator and Influencer.

New Study Indicates Reversal of Hair Greying Process Might Be Possible

Subscribe to get Latest News Updates

Latest News

You may like more
more

NASA Declares No Intention to Use SpaceX for Rescuing Boeing Starliner Astronauts

  Two astronauts who were supposed to return to Earth...

Fake Therapist Fooled Hundreds Online Until She Died, State Records Say

July 2, 2024 Hundreds of Americans may have unknowingly...

Organic Greek Vitamin C’s Breakthrough Role in Giant Pimple Blackhead Removal: CWEB Reports

Organic Greek Vitamin C: Your Solution to Blackheads, Pimples,...